T-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis

Trial Details

NCT ID

NCT07150208

Phase

PHASE2

Sponsor

Fudan University

Status

RECRUITING

Cancer Type

Breast Cancer

Interventions

• Bevacizumab (Bev)
• Trastuzumab Deruxtecan (T-DXd)

Locations (sample)

• Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

• ECOG score of 0 to 1.
• Expected survival period greater than 12 weeks.
• Histologically confirmed invasive HER2-low expressing breast cancer (specific definition: breast cancer patients with low expression of human epide…
• Tumor stage: recurrent or metastatic breast cancer; local recurrence must be confirmed by the researcher to be unable to undergo radical surgical r…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.